Researchers at the University of Virginia School of Medicine have identified an unexpected contributor to rheumatoid arthritis that may help explain the painful flare-ups associated with the disease. The discovery points to a potential new treatment for the autoimmune disorder and may also allow the use of a simple blood test to detect people at elevated risk for developing the condition.
The promising discovery is among the first to emerge from the School of Medicine’s new affiliation with Inova Health, a collaboration that aims to make medical breakthroughs and advance the battle against disease. In this case, the arthritis discovery originated in the lab of UVA’s Kodi Ravichandran, PhD, and was facilitated by combining his team’s resources and expertise with that of Inova researcher Thomas Conrads, PhD, through a THRIV UVA-Inova seed grant.
Understanding Rheumatoid Arthritis
The new findings about rheumatoid arthritis came in an unexpected fashion. Sanja Arandjelovic, PhD, a research scientist in the Ravichandran group, was seeking to better understand what causes the inflammation associated with inflammatory arthritis when she noted that deleting a gene called ELMO1 alleviated arthritis symptoms in mice. This was particularly surprising because Arandjelovic and Ravichandran initially thought that loss of ELMO1 would result in increased inflammation.
“This was a complete surprise to us initially,” recalled Ravichandran, chairman of UVA’s Department of Microbiology, Immunology and Cancer Biology. “I love those kinds of results, because they tell us that, first, we did not fully comprehend the scientific problem when we began exploring it, and, second, such unexpected results challenge us to think in a different way. Given that rheumatoid arthritis affects millions of people worldwide, we felt the need to understand this observation better.”
Digging deeper into the unusual outcome, the researchers determined that ELMO1 promotes inflammation via their function in white blood cells called neutrophils. Ravichandran described neutrophils as the body’s “first line of defense” because they sense and respond to potential threats. “Normally they are good for us, against many bacterial infections,” he said. “But also there are many times when they produce a lot of friendly fire that is quite damaging to the tissues – when they hang around too long or there are too many neutrophils coming in – in this case, infiltrating into the joints during arthritis.”
The researchers also discovered that there is a natural variation in the ELMO1 gene that can prompt neutrophils to become more mobile and have the potential to invade the joints in greater numbers and induce inflammation. (The potential blood test would detect this variation.)
Here things take a particularly cool turn: Normally, doctors are reluctant to try to block the effect of genes like ELMO1 in people, because such genes can play diverse roles in the body. But Ravichandran believes that ELMO1 is different. “ELMO1 partners with very specific set of proteins only in the neutrophils but not in other cells types we tested,” he said. “So, presumably, you may be able to affect only a select cell type.” This latter result came about from a collaborative study where Conrads’ group at Inova performed sophisticated analysis of ELMO1 proteomic partners in neutrophils, many of which also have previously known links to human arthritis. This provided further validation for the role of ELMO1 in rheumatoid arthritis.
Encouragingly, blocking ELMO1 in lab mice alleviated arthritis inflammation without causing other problems, Ravichandran noted. His laboratory is now seeking to identify drugs that could inhibit the function of ELMO1 and is also designing a test for the variation (also called polymorphism) in the ELMO1 gene.
“This is another example of how fundamental basic research can lead to novel discoveries on clinically relevant problems that affect a large number of people,” Ravichandran said.
The Latest on: Rheumatoid arthritis
[google_news title=”” keyword=”rheumatoid arthritis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Rheumatoid arthritis
- Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Marketon February 23, 2024 at 11:50 am
Practicing rheumatologists report that among the RA patients under their management, on average, 57% are currently treated with advanced systemic therapies, with an additional 22% of patients ...
- Clinical Trial Led by King’s College London Demonstrates Potential of Rheumatoid Arthritis Drug in Disease Preventionon February 23, 2024 at 3:55 am
Results from a Phase 2b clinical trial, published today in The Lancet by researchers led by King’s, provides hope for arthritis sufferers after it was shown that the biologic drug abatacept reduces pr ...
- Can Rheumatoid Arthritis Treatment Reduce Bone Density? Know From A Doctoron February 21, 2024 at 10:56 pm
"Bone density measurement plays a crucial role in the management of RA. Monitoring it enables doctors to assess the extent of bone loss and determine appropriate interventions to minimise fracture ...
- Breakthrough: New Drug Might Halt Rheumatoid Arthritis in Those Most at Riskon February 19, 2024 at 3:27 pm
A drug already used to alleviate some of the painful symptoms of rheumatoid arthritis might also be effective at stopping it from developing to begin with – potentially saving millions of people from ...
- Can rheumatoid arthritis be prevented? | Explainedon February 17, 2024 at 12:58 pm
Can rheumatoid arthritis be delayed by repurposing an existing drug? Where does India stand on treating this autoimmune disease?
- Acupuncture may help reduce stroke risk in people with rheumatoid arthritison February 17, 2024 at 5:00 am
Researchers have found that a course of acupuncture may help reduce the heightened risk of stroke associated with rheumatoid arthritis by 43%.
- Another Study Backs Treatment for Preclinical Rheumatoid Arthritison February 15, 2024 at 4:00 pm
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Inflammatory markers were reduced in patients with persistent joint pain and other markers for incipient rheumatoid ...
- Drug Used to Treat Rheumatoid Arthritis May Also Help Prevent Iton February 15, 2024 at 4:58 am
Day’s clinical trial showed that abatacept also is effective in preventing the onset of rheumatoid arthritis. About 6% of patients treated with abatacept developed arthritis compared to 29% given a ...
- Rheumatoid Arthritis Drug Abatacept Shown to Prevent Disease in Clinical Trialon February 15, 2024 at 3:16 am
A new clinical trial found that abatacept, a drug used to treat rheumatoid arthritis, may also help to prevent the disease.
- Rheumatoid arthritis can be prevented, study showson February 13, 2024 at 3:30 pm
Rheumatoid arthritis can be prevented, a breakthrough Lancet study has found. Weekly injections of the drug, abatacept, cut the risk of developing the auto-immune disease by 80 per cent during a trial ...
via Bing News